Published in Circulation on August 25, 2003
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest (2006) 4.50
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials (2006) 2.50
An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res (2007) 1.57
Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology (2009) 1.19
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis (2007) 1.09
Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur J Clin Pharmacol (2012) 1.08
Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood (2006) 1.03
Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag (2015) 0.96
Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. Br J Clin Pharmacol (2006) 0.93
4 years after withdrawal of rofecoxib: where do we stand today? Rheumatol Int (2008) 0.90
Prospective, observational study of antiplatelet and coagulation biomarkers as predictors of thromboembolic events after implantation of ventricular assist devices. Nat Clin Pract Cardiovasc Med (2009) 0.88
The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J (2004) 0.87
Selective COX-2 inhibitors, NSAIDs and cardiovascular events - is celecoxib the safest choice? Ther Clin Risk Manag (2007) 0.87
The emerging role of oxylipins in thrombosis and diabetes. Front Pharmacol (2014) 0.85
Aspirin resistance. BMJ (2004) 0.84
The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol (2009) 0.83
Place of OTC analgesics and NSAIDs in osteoarthritis. Inflammopharmacology (2003) 0.82
Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs? Can Fam Physician (2007) 0.80
[Pharmacological treatment of osteoarthritis in the elderly]. Z Rheumatol (2005) 0.79
Migraine and cardiovascular disease in women and the role of aspirin: subgroup analyses in the Women's Health Study. Cephalalgia (2011) 0.79
Giving aspirin and ibuprofen after myocardial infarction. BMJ (2003) 0.77
Searching for factors associated with resistance to acetylsalicylic acid used for secondary prevention of stroke. Arch Med Sci (2015) 0.75
Throw away the aspirin and take nonsteroidal anti-inflammatory drugs for the primary prevention of myocardial infarction. Circulation (2004) 0.75
Do NSAIDs inhibit the cardioprotective effects of ASA? CMAJ (2004) 0.75
Resistance to acetylsalicylic acid in patients with type 2 diabetes mellitus is associated with lipid disorders and history of current smoking. J Endocrinol Invest (2014) 0.75
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2004) 0.75
[Primary prevention of coronary heart disease with aspirin]. Z Kardiol (2005) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet (2009) 10.52
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology (2009) 7.40
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J (2004) 6.57
Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med (2009) 6.16
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet (2008) 5.49
A randomized study of how physicians interpret research funding disclosures. N Engl J Med (2012) 5.47
Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28
Physical activity and weight gain prevention. JAMA (2010) 5.27
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA (2004) 5.25
Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 5.25
Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf (2006) 5.16
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 5.13
Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ (2009) 4.98
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Prescription drug use in pregnancy. Am J Obstet Gynecol (2004) 4.92
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA (2011) 4.73
Full coverage for preventive medications after myocardial infarction. N Engl J Med (2011) 4.51
The comparative safety of analgesics in older adults with arthritis. Arch Intern Med (2010) 4.47
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46
Prevalence of dry eye syndrome among US women. Am J Ophthalmol (2003) 4.46
Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem (2007) 4.45
Multivitamins in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2012) 4.40
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med (2012) 4.10
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med (2002) 4.07
Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. J Am Coll Cardiol (2009) 3.99
A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol (2011) 3.98
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol (2004) 3.53
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst (2008) 3.40
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. Arch Intern Med (2007) 3.37